Prestige Consumer Healthcare (NYSE:PBH) Cut to Hold at Wall Street Zen

Wall Street Zen lowered shares of Prestige Consumer Healthcare (NYSE:PBHFree Report) from a buy rating to a hold rating in a research note issued to investors on Saturday.

A number of other equities research analysts have also commented on the company. Canaccord Genuity Group lowered their price target on Prestige Consumer Healthcare from $105.00 to $100.00 and set a “buy” rating for the company in a research report on Friday. Royal Bank Of Canada raised Prestige Consumer Healthcare to a “hold” rating in a research report on Thursday, May 8th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $93.33.

View Our Latest Analysis on PBH

Prestige Consumer Healthcare Price Performance

Shares of NYSE:PBH opened at $64.04 on Friday. The firm has a market capitalization of $3.15 billion, a price-to-earnings ratio of 15.03, a PEG ratio of 1.98 and a beta of 0.43. The stock’s 50 day moving average is $78.83 and its 200-day moving average is $82.00. Prestige Consumer Healthcare has a twelve month low of $63.49 and a twelve month high of $90.04. The company has a quick ratio of 2.99, a current ratio of 4.38 and a debt-to-equity ratio of 0.55.

Prestige Consumer Healthcare (NYSE:PBHGet Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.95 EPS for the quarter, missing analysts’ consensus estimates of $1.01 by ($0.06). The company had revenue of $249.53 million during the quarter, compared to analysts’ expectations of $260.71 million. Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The company’s quarterly revenue was down 6.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.90 earnings per share. Sell-side analysts forecast that Prestige Consumer Healthcare will post 4.5 EPS for the current fiscal year.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Several large investors have recently added to or reduced their stakes in PBH. UMB Bank n.a. increased its holdings in Prestige Consumer Healthcare by 81.8% in the 2nd quarter. UMB Bank n.a. now owns 320 shares of the company’s stock worth $26,000 after acquiring an additional 144 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in Prestige Consumer Healthcare by 312.5% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company’s stock worth $26,000 after purchasing an additional 250 shares during the period. Maseco LLP bought a new position in Prestige Consumer Healthcare in the 2nd quarter worth about $27,000. Opal Wealth Advisors LLC bought a new position in Prestige Consumer Healthcare in the 1st quarter worth about $38,000. Finally, First Horizon Advisors Inc. boosted its stake in Prestige Consumer Healthcare by 294.1% in the 2nd quarter. First Horizon Advisors Inc. now owns 599 shares of the company’s stock worth $48,000 after purchasing an additional 447 shares during the period. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

(Get Free Report)

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

Featured Stories

Analyst Recommendations for Prestige Consumer Healthcare (NYSE:PBH)

Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.